Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 31Lymphoma 19Neoplasms, Plasma Cell 16Myelodysplastic Syndromes 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, Non-Hodgkin 13Leukemia, Myeloid, Acute 13Leukemia 13Hodgkin Disease 12Leukemia, Lymphocytic, Chronic, B-Cell 9Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 7Retinoblastoma 6Lymphoma, Mantle-Cell 6Burkitt Lymphoma 6Myeloproliferative Disorders 5Immunoglobulin Light-chain Amyloidosis 5Recurrence 4Primary Myelofibrosis 4Ovarian Neoplasms 4Neuroblastoma 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myelomonocytic, Juvenile 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hematologic Neoplasms 4Congenital Abnormalities 4Sezary Syndrome 3Myelodysplastic-Myeloproliferative Diseases 3

Interventions

Paclitaxel 18Carboplatin 14Topotecan 8liposomal doxorubicin 6Cyclophosphamide 5Cisplatin 5Gemcitabine 4Docetaxel 4oregovomab 3Immunoenzyme Techniques 3Etoposide 3Capecitabine 3pembrolizumab 2fludarabine phosphate 2aldesleukin 2Taxes 2Surgical Procedures, Operative 2Stem Cell Transplantation 2STA 9090 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Nivolumab 2Microarray Analysis 2Magnetic Resonance Spectroscopy 2Lenalidomide 2Fulvestrant 2Fluorodeoxyglucose F18 2Flow Cytometry 2Filgrastim 2Cytoreduction Surgical Procedures 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Ovarian Epithelial × Melphalan × Clear all
NCT00583622 2013-05-21

Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients

M.D. Anderson Cancer Center

Phase 2 Terminated
13 enrolled 5 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡